Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tonix Pharma ( (TNXP) ) just unveiled an announcement.
On December 29, 2025, Tonix Pharmaceuticals entered into a securities purchase agreement with a single institutional investor for a registered direct offering comprising 615,025 shares of common stock and pre-funded warrants to purchase an additional 615,025 shares, at per-share and per-warrant prices of $16.26 and $16.259, respectively. The transaction, expected to close on or about December 30, 2025, is anticipated to generate approximately $20 million in gross proceeds and includes standard terms such as ownership caps on warrant exercises, short-term restrictions on Tonix issuing additional equity or variable-rate securities, and 30-day lock-up agreements for directors and officers; TD Securities (USA) LLC is acting as placement agent and will receive a 6% cash fee on the gross proceeds, underscoring Tonix’s continued reliance on equity-linked financings to support its operations and balance sheet while signaling to stakeholders a willingness to accept issuance constraints in exchange for near-term capital.
The most recent analyst rating on (TNXP) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall score is driven by its financial challenges and neutral technical indicators. However, recent corporate events suggest potential for future growth. The negative valuation metrics weigh heavily on the score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a biotechnology company operating in the pharmaceutical industry, focused on developing and commercializing therapeutic products, with its securities actively traded and financed through U.S. capital markets.
Average Trading Volume: 734,222
Technical Sentiment Signal: Sell
Current Market Cap: $191.5M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.